Dimapur News Desk

Respiratory Syncytial Virus Infections Epidemiology Forecast to 2030 by DelveInsight

 Breaking News
  • No posts were found

Respiratory Syncytial Virus Infections Epidemiology Forecast to 2030 by DelveInsight

February 02
17:10 2021
Respiratory Syncytial Virus Infections Epidemiology Forecast to 2030 by DelveInsight

DelveInsight has launched a new report on Respiratory Syncytial Virus Infections Epidemiology

 

Respiratory syncytial virus, or RSV, is a common respiratory virus that usually causes mild, cold-like symptoms. Most people recover in a week or two, but RSV can be serious, especially for infants and older adults. In fact, RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than 1 year of age in the United States. It is also a significant cause of respiratory illness in older adults.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-epidemiology-forecast

 

Respiratory Syncytial Virus Infections Epidemiology Historical as well as forecasted epidemiology in the United States, EU5, Japan and China from 2017 to 2030

 

Respiratory Syncytial Virus Infections Epidemiology

Respiratory syncytial virus (RSV) is a widespread pathogen of humans, due in part to the lack of long-term immunity after infection, making reinfection frequent. It infects 90% of children within the first 2 years of life and frequently reinfects older children and adults. The majority of patients with RSV will have an upper respiratory illness, but a significant minority will develop lower respiratory tract illness, predominantly in the form of bronchiolitis. Children under the age of one year are especially likely to develop lower respiratory involvement, with up to 40% of primary infections resulting in bronchiolitis.

 

Key facts of the Respiratory Syncytial Virus Infections Epidemiology report

  • Over 57,000 hospitalizations, 500,000 emergency department visits and 1.5 million outpatient clinic visits among children
  • Among US adults, an estimated 177,000 hospitalizations and 14,000 deaths associated with RSV infections occur annually.
  • As per the study conducted by Tin Htar et al. (2020), incidence rates of hospitalized RSV acute tract infections in age group of >65 years ranged from7.3 to 13.0/105 population in Africa and Asia and from 190 to 254/105 population in the USA. Very high incidence rates (195–1790/105 population) were seen in adults>=50 years for emergency visits in United States.

 

Respiratory Syncytial Virus Infections Epidemiology Segmentation

  • Total Incident Cases of Respiratory Syncytical Virus in the 7MM (2017-2030)
  • Diagnosed and Treatable cases of Respiratory Syncytical Virus in the 7MM (2017-2030)
  • Age-specific Incidence of Respiratory syncytial virus in 7MM (2017–2030)

 

Respiratory Syncytial Virus Infections Symptoms

Symptoms of RSV infection usually include runny nose; decrease in appetite; coughing; sneezing fever; wheezing. These symptoms usually appear in stages and not all at once. In very young infants with RSV, the only symptoms may be irritability, decreased activity, and breathing difficulties. RSV can also cause more severe infections such as bronchiolitis, an inflammation of the small airways in the lung, and pneumonia, an infection of the lungs. It is the most common cause of bronchiolitis and pneumonia in children younger than 1 year of age. People infected with RSV usually show symptoms within 4 to 6 days after getting infected.

 

Respiratory Syncytial Virus Infections Treatment

Treatment for RSV falls into three categories: supportive care, immune prophylaxis, and antiviral medication. The majority of RSV and bronchiolitis cases require no specific medical intervention, and many attempted treatments throughout history are ineffective. Vaccines for RSV and therapeutic interventions in RSV remain a target of intense scientific interest.

Many other treatment modalities for bronchiolitis have been tried in the past, and all others have failed to show broad, reproducible efficacy on clinically significant outcomes in RSV and bronchiolitis. These include albuterol, racemic epinephrine, steroids, hypertonic saline, antibiotics, and chest physical therapy, and routine use of these interventions is not recommended. Future vaccines could potentially decrease the economic burden of RSV in the healthcare setting.

 

Respiratory Syncytial Virus Infections Report Scope

  • The Respiratory syncytial virus (RSV) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns
  • The Respiratory syncytial virus (RSV) Epidemiology Report and Model provide an overview of the risk factors and global trends of Respiratory syncytial virus (RSV) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Respiratory syncytial virus (RSV) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Respiratory syncytial virus (RSV)
  • The report provides the segmentation of the Respiratory syncytial virus (RSV) epidemiology

 

Request for free sample copy- https://www.delveinsight.com/sample-request/respiratory-syncytial-virus-rsv-epidemiology-forecast

 

Table of content

1. Key Insights 

2. Executive Summary of Respiratory syncytial virus (RSV)

3. Respiratory syncytial virus (RSV): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Reasons to buy

The Respiratory syncytial virus (RSV) Epidemiology report will allow the user to –

  • Develop business strategies by understanding the trends shaping and driving the global Respiratory syncytial virus (RSV) market
  • Quantify patient populations in the global Respiratory syncytial virus (RSV) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Respiratory syncytial virus (RSV) therapeutics in each of the markets covered
  • Understand the magnitude of Respiratory syncytial virus (RSV) population by its epidemiology
  • The Respiratory syncytial virus (RSV) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Report

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/dimapurnewsdesk/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share